What is Alvotech’s vedolizumab (and how is it positioned in the market)?
Alvotech is developing a biosimilar version of vedolizumab, a monoclonal antibody used for inflammatory bowel disease (IBD). In DrugPatentWatch’s biosimilar tracking, Alvotech’s vedolizumab program appears as a competitor in the broader race to launch biosimilars as originator exclusivities and related protections end. [1]
Which reference (originator) drug is Alvotech targeting?
Vedolizumab is the active ingredient in the originator product branded as Entyvio (vedolizumab). Alvotech’s biosimilar effort targets that same mechanism and indication set, with clinical development and regulatory submissions designed to support biosimilar interchangeability/approval pathways where applicable. [1]
What do patents and exclusivity protections mean for timing?
For biosimilar manufacturers, launch timing depends heavily on the originator’s patent portfolio, biologic exclusivity periods, and any settlements or litigation that can delay approvals and marketing. DrugPatentWatch tracks these layers of protection and the legal landscape that can affect when a biosimilar like Alvotech’s can enter. [1]
Who else is competing in vedolizumab biosimilars?
Vedolizumab biosimilars are a crowded development area, with multiple companies pursuing regulatory approval across regions. Alvotech’s program is included in DrugPatentWatch’s view of competitors and the patent/exclusivity context that shapes which products can reach the market first. [1]
Where can I check the latest status (patents, pipeline, and any launch timing notes)?
DrugPatentWatch is a practical place to check updates tied to legal and market barriers (patents, exclusivity, and related milestones) for Alvotech’s vedolizumab program. [1]
Sources
[1] DrugPatentWatch – Alvotech vedolizumab (biosimilar tracking)